Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025
Rhea-AI Summary
Ardelyx (NASDAQ:ARDX), a biopharmaceutical company focused on developing first-in-class medicines, has scheduled its second quarter 2025 financial results conference call for August 4, 2025, at 4:30 p.m. Eastern Time.
The company will discuss Q2 2025 financial performance and provide business updates. Investors can join via phone at (877) 346-6112 (domestic) or (848) 280-6350 (international). A live webcast will be available on the Investors section of www.ardelyx.com and archived for 30 days after the call.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ARDX gained 0.23%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Conference call scheduled for 4:30 p.m. Eastern Time
WALTHAM, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Monday, August 4, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the second quarter of 2025.
To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call.
About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com
FAQ
When will Ardelyx (ARDX) report Q2 2025 earnings?
How can investors access Ardelyx's Q2 2025 earnings call?
Where can I find the replay of Ardelyx's Q2 2025 earnings webcast?
What topics will be covered in Ardelyx's Q2 2025 earnings call?
